Table 1 Patients’ baseline demographics and tumour characteristics
Characteristic | n(range)/ (%) |
|---|---|
Total Patients | 55 (100%) |
Age in years | 50 (24–80) |
Type of cancer | Â |
 Invasive ductal carcinoma | 49 (89.1%) |
 Ductal carcinoma in situ | 2 (3.6%) |
 Invasive lobular carcinoma | 2 (3.6%) |
 Lobular carcinoma in situ | 2 (3.6%) |
Tumor classification | Â |
 T1 | 11 (20%) |
 T2 | 34 (61.8%) |
 T3 | 8 (14.5%) |
 T4 | 2 (3.6%) |
Nodal status | Â |
 N0 | 16 (29.1%) |
 N1 | 17 (30.9%) |
 N2 | 18 (32.7%) |
 N3 | 4 (7.3%) |
Metastasis Status | Â |
 M0 | 42 (76.4%) |
 M1 | 8 (14.5%) |
 Mx | 5(9.1%) |
Surgery type | Â |
 Mastectomy (without prosthesis) | 43 (78%) |
 Mastectomy (with prosthesis) | 0 (0%) |
 Breast conservation surgery | 12 (22%) |
Prescribed dose | 42.56Â Gy/16 fractions |
Adjuvant therapy | Â |
Chemotherapy | 33 (60%) |
Endocrine therapy | 17 (30.9%) |
Targeted therapy | 5 (9.1%) |
 - Herceptin | 4 (7.3%) |
 - Pembrolizumab | 1 (1.8%) |